[London, 18 May 2022] – The developers of Augnito a secure, cloud-based and AI-driven clinical speech recognition product suite, have recorded dramatic Q1 growth in the UK following the launch of its new flagship solution.
Clinical speech recognition (SR) solutions developer, Scribetech, has recorded rapid sales growth for its recently launched secure and portable AI-driven clinical SR product suite Augnito, which offers fast, effortless ways to capture live clinical data, on any device, with 99.3% accuracy.
Augnito was launched in late 2021 with active sales taking off in Q1 2022, its first UK trading quarter. The company has already secured in excess of 150 implementations in healthcare environments across England and a number of live pilots with NHS Trusts are also underway. The uplift has been driven by demand for its solution in the radiology sector, which has soared as the health service deals with the backlogs in imaging and reporting created by the pandemic.
The developers of Augnito are now setting their sights higher, aiming for sustained sales growth in its next financial year and is determined to continue to disrupt the clinical SR healthcare market. To help drive that, the business has also launched a dedicated channel program looking to sign up value-added resellers and managed service providers that have a healthcare focus and the technical skills necessary to deliver IT solutions for the market.
Shiraz Austin, Co-Founder for Augnito & Managing Director at Scribetech (UK) Ltd, said: “From the outset, Augnito was built in close partnership with clinicians, using human-centred design, to create a Natural Language Processing engine to fit their needs – not the other way round. As a result, Augnito offers excellent support for a wide variety of clinical vocabulary and workflows and this is what has driven market interest in, and sales of, our voice-AI solution.”
Since the beginning of the year Augnito has also been signed up by a number of strategic technology partners where its API and SDK product is augmenting workflows with cutting-edge technology to transform healthcare institutions to improve patient care across all departments.
Partnerships already underway include a leading supplier of specialist clinical information solutions Wellbeing Software, Cimar, a cloud-native health information medical imaging platform, and Hexarad, a UK leading teleradiology service provider and one of the UK’s fastest growing start-ups.
“We are extremely pleased with our performance. It’s really a strong validation of our vision and product capabilities; customers are increasingly looking to solutions such as ours which address a number of core issues that confront those on the healthcare frontline, such as improving efficiency and accuracy, as well as optimising clinical workflows,” added Austin.
Augnito is a secure and portable AI-driven clinical SR product suite that offers fast, effortless ways to capture live clinical data, on any device, with 99.3% accuracy. The SaaS cloud-based solution is proven to create highly accurate clinical records, improving the timing on everything from patient diagnosis to patient hospital stays in delayed transfers of care. Radiology departments have been the earlier adopters and pioneers of speech recognition technology to accommodate the ever-increasing levels of a wide variety of diagnostic reporting and the ever-expanding modality spectrum. Augnito now offers this sector an improved, more efficient way, to deliver their service using the benefits that voice-driven AI technology has to offer.
Developed as a cloud-based technology by Scribetech and based on 20 years of hands-on-experience delivering transcription and digital dictation services to the NHS, Augnito removes the need for healthcare IT teams to support the solution with additional hardware and/or software. Product application enhancements are also delivered in the cloud as soon as they are ready for release, without the need to upgrade locally installed versions. This reduces dependency on IT resource teams, potential associated product downtime, delays, and costs.
Austin concluded: “The investment we have made year-to-date represents the biggest outside of our Indian market. Furthermore, we have made additional investments in growing our UK channel footprint, with new management expertise now in place specifically to develop those partner relationships.”
“As we enter our new financial year, we have our sights on further international expansion powered by the growth in sales and revenue. It is our intention to add to a global Augnito team with our eyes firmly on the USA, APAC and Midle Eastern markets in the immediate term building on our successes here in the UK and India.”